Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2021-09-21 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed instructions and fields related to filing reports of exempt distributions in Canadian jurisdictions. It includes regulatory references to Canadian securities authorities, filing instructions, and specific data fields for issuers and underwriters. The content is a regulatory form used for reporting exempt distributions of securities, not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities distribution compliance rather than a corporate financial or governance report. Therefore, the document fits best under the category of Regulatory Filings (RNS).
2021-09-21 English
News release - French.pdf
Regulatory Filings
2021-09-13 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the issuance of units in settlement of interest owed to debenture holders. It details the terms of the issuance, including the number of units, unit price, and warrants attached. The document does not contain financial statements, detailed financial performance data, or comprehensive financial analysis. It is an update on a financing activity related to the company's capital structure. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content fits the category of a Capital/Financing Update, as it relates to the issuance of securities to settle debt interest and involves approval by the TSX Venture Exchange. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-09-08 English
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the issuance of units in settlement of interest owed to debenture holders. It details the number of units, their price, and conditions such as TSX Venture Exchange approval and a hold period. The content focuses on a financing activity involving issuance of securities to settle debt interest. There are no financial statements, quarterly or annual results, nor is this a report or presentation. The document is not a regulatory filing or certification but a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5927 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2021-09-08 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new exclusive distribution, sales, and marketing agreement for a product line (Purgenesis™ Anti-aging Products) in Middle East countries. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. The content focuses on a business development and partnership announcement rather than a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The document is best classified as a general regulatory announcement about a business agreement, which fits the category of Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2021-08-31 English
News release - French.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing an exclusive distribution, sales, and marketing agreement for anti-aging products in the Middle East by Groupe Santé Devonian. It details the terms of the agreement, the companies involved, product descriptions, and forward-looking statements. There is no financial data, no regulatory filing references, no meeting materials, no voting results, no management or board changes, no earnings or interim report data, and no audit or legal proceedings information. The document is a corporate announcement about a commercial partnership and not a financial report or regulatory filing. Therefore, it best fits the category of Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing that does not fit other categories.
2021-08-31 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.